The key innovation of this study is the clear and systematic demonstration that inhibiting KMO activity significantly ameliorates the core behavioral symptoms of epilepsy-associated depression (e.g., anhedonia and behavioral despair) and cognitive dysfunction. This evidence concerns the gene KMO and depressive symptom measurement.